Melio Bio
Targeting GPR75
Specifically, for Melio Bio we are working to develop small-molecule inverse agonists against GPR75. Widely recognised as a genetically validated target for next-generation obesity therapeutics, we believe that by inhibiting this G-protein coupled receptor (GPCR) adiposity will be reduced and healthy muscle mass will be preserved. Our therapeutic strategy surrounding GPR75 extends beyond an isolated treatment for obesity to address a broader spectrum of interconnected cardiometabolic pathologies where this pathway is critically implicated. By leveraging clinical data to map specific risk factors, we aim to intercept and halt the progression of severe comorbidities driven by GPR75 dysregulation.
Strategic Project Team
Melio Bio has established critical project partnerships with Sygnature Discovery and the University of Aberdeen to leverage deep GPR75 target expertise and success in developing potent and selective modulators of drug targets, including GPCRs. The team is being guided by industry experts as the program moves towards the clinic.
Pod Expansion
In line with the MTM global vision, the MTM team continues to identify novel targets, evaluate assets and build strategic collaboration opportunities to scale and build out our cardiometabolic pod.
